ZA928607B - Compositions and methods for preventing adhesion formulation. - Google Patents

Compositions and methods for preventing adhesion formulation.

Info

Publication number
ZA928607B
ZA928607B ZA928607A ZA928607A ZA928607B ZA 928607 B ZA928607 B ZA 928607B ZA 928607 A ZA928607 A ZA 928607A ZA 928607 A ZA928607 A ZA 928607A ZA 928607 B ZA928607 B ZA 928607B
Authority
ZA
South Africa
Prior art keywords
rgd
compositions
methods
peptide
preventing adhesion
Prior art date
Application number
ZA928607A
Other languages
English (en)
Inventor
Gere Stodder Dizerega
Kathleen Elizabeth Rodgers
Original Assignee
Univ Southern Calofornia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern Calofornia filed Critical Univ Southern Calofornia
Publication of ZA928607B publication Critical patent/ZA928607B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ZA928607A 1991-11-07 1992-11-09 Compositions and methods for preventing adhesion formulation. ZA928607B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78923191A 1991-11-07 1991-11-07

Publications (1)

Publication Number Publication Date
ZA928607B true ZA928607B (en) 1993-06-07

Family

ID=25146991

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA928607A ZA928607B (en) 1991-11-07 1992-11-09 Compositions and methods for preventing adhesion formulation.

Country Status (8)

Country Link
US (1) US5629294A (fr)
EP (1) EP0667783B1 (fr)
AT (1) ATE179074T1 (fr)
AU (1) AU3064892A (fr)
DE (1) DE69229004D1 (fr)
TW (1) TW269634B (fr)
WO (1) WO1993008818A1 (fr)
ZA (1) ZA928607B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
DE19529909C2 (de) * 1995-08-15 1998-04-09 Fresenius Ag Wässrige Spüllösung
EP0793965A3 (fr) * 1996-02-29 1999-02-24 Tano, Yasuo Composition prophylactique/thérapeutique pour cataracte secondaire
JP4234803B2 (ja) * 1997-10-27 2009-03-04 久光製薬株式会社 薬物放出速度が制御された医薬組成物
WO2000004941A1 (fr) * 1998-07-24 2000-02-03 Pharmacal Biotechnologies, Inc. Systeme et procede de reconstruction de tissus osseux
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US6312725B1 (en) 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
JP2003500171A (ja) * 1999-06-01 2003-01-07 ブリストル−マイヤーズ スクイブ カンパニー より炎症性応答の少ないフィブリンシーラントおよびこれを用いる方法
AU2001236909A1 (en) * 2000-02-11 2001-08-20 Duke University Method of treating disorders of the eye
EP1845107B1 (fr) * 2003-03-28 2019-05-29 FUJIFILM Manufacturing Europe B.V. Système d'administration de medicaments comprenant des protéines de type gélatine enrichies en RGD avec une liaison cellulaire améliorée
WO2005053683A1 (fr) * 2003-11-26 2005-06-16 Duke University Technique de prevention ou de traitement du glaucome
CN104174071A (zh) 2004-04-28 2014-12-03 安希奥设备国际有限责任公司 用于形成交联生物材料的组合物和系统及关联的制备方法与用途
EP1984391A4 (fr) * 2006-01-19 2009-08-12 Eyegene Inc Composition pharmaceutique a base de peptide pour le traitement de maladies vasculaires
CN101379082A (zh) 2006-01-19 2009-03-04 爱吉恩公司 治疗血管相关疾病的包含肽的药物组合物
US9101581B2 (en) 2008-10-27 2015-08-11 Eyegene Inc. Method for treating vascular-related disease
AU2008303955A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of Pseudomonas aeruginosa infection
CA2698754A1 (fr) * 2007-09-11 2009-03-19 Dorian Bevec Utilisation d'un peptide en tant qu'agent therapeutique
RU2010113971A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение пептида yy отдельно или в сочетании с глюкагоноподобным пептидом для применения в медицине
AU2008297899A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of human neuropeptide as a therapeutic agent
US20110250284A1 (en) * 2008-06-24 2011-10-13 Lavik Erin B Nanoparticles for Use as Synthetic Platelets and Therapeutic Agent Delivery Vehicles
US9555071B2 (en) * 2012-06-13 2017-01-31 Thien Nguyen Methods and compositions for the treatment of axonal and neuronal degeneration

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661111A (en) * 1982-08-04 1987-04-28 La Jolla Cancer Research Foundation Polypeptide
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4517686A (en) * 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4614517A (en) * 1982-08-04 1986-09-30 La Jolla Cancer Research Foundation Tetrapeptide
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
DE3781263T2 (de) * 1986-12-15 1993-04-08 Inst Nat Sante Rech Med Peptid-derivate und deren verwendung in der therapie.
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
CA2008534A1 (fr) * 1989-01-26 1990-07-26 Donald E. Ingber Methode pour empecher la reapparition des tumeurs apres resection chirurgicale
NZ235564A (en) * 1989-10-13 1993-10-26 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical compositions
NZ235563A (en) * 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
US5169833A (en) * 1989-12-15 1992-12-08 G. D. Searle & Co. Substituted cyclic pentapeptides

Also Published As

Publication number Publication date
DE69229004D1 (de) 1999-05-27
WO1993008818A1 (fr) 1993-05-13
ATE179074T1 (de) 1999-05-15
US5629294A (en) 1997-05-13
EP0667783A4 (fr) 1995-04-25
AU3064892A (en) 1993-06-07
EP0667783B1 (fr) 1999-04-21
TW269634B (fr) 1996-02-01
EP0667783A1 (fr) 1995-08-23

Similar Documents

Publication Publication Date Title
TW269634B (fr)
US4474753A (en) Topical drug delivery system utilizing thermosetting gels
FI970522A0 (fi) Koostumukset ja menetelmät pidennetyn paikallisanestesian aikaansaamiseksi
IL119627A0 (en) Controlled-release pharmaceutical preparations
CA2203033A1 (fr) Composes et compositions pour l'administration d'agents actifs
RU2004111596A (ru) Офтальмические композиции в форме депо для периокулярного или субконъюнктивального введения
CA2271750A1 (fr) Anesthesie a effet prolonge injectee dans les interlignes articulaires et corporelles
ATE211387T1 (de) Oral 1alpha-hydroxyprevitamin d
GR3036798T3 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
ATE167800T1 (de) Polymeres arzneimittelabgabesystem
NZ333724A (en) Enhancing lean tissue mass and bone mineral content by the administration of calcium compositions
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
TW228474B (fr)
IE61346B1 (en) A permeable material to fit around the teeth or gums of a mammal
ES2111163T3 (es) Uso de fosfonatos para el tratamiento de la osteoporosis.
DE69622739D1 (de) Pharmazeutische zubereitung mit schneller freisetzung
CA2156481A1 (fr) Compositions antagonistes du recepteur 5-ht2, utiles pour le traitement des troubles veineux
ATE136773T1 (de) Kollagenmikrokapseln enthaltende injezierbare zusammensetzung
ATE289506T1 (de) Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren
Carroll et al. The histologic effect of topically applied acetylsalicylic acid on bone healing in rats
Nawata et al. Bone Regeneration in Femoral Defect Filled with Fibrin Sealant. An Experimental Study
CA2187153A1 (fr) Formulations pharmaceutiques effervescentes contenant des microgelules biodegradables a liberation controlee
MX9709904A (es) Formulaciones de hidroxiapatita biocompatibles y usos de las mismas.
TH16407B (th) วิธีการผลิตกลูตาไธโอนที่มีขนาดยาสูงยาเม็ดและยาหลอดที่ผลิตโดยวิธีนี้